Cargando…
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Four cell lines, the mouse L1210 leukaemia, the human W1L2 lymphoblastoid and two human ovarian (CH1 and 41M) cell lines, were made resistant to ZD1694 (Tomudex) by continual exposure to incremental doses of the drug. A 500-fold increase in thymidylate synthase (TS) activity is the primary mechanism...
Autores principales: | Jackman, A. L., Kelland, L. R., Kimbell, R., Brown, M., Gibson, W., Aherne, G. W., Hardcastle, A., Boyle, F. T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033796/ https://www.ncbi.nlm.nih.gov/pubmed/7537518 |
Ejemplares similares
-
Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
por: Aherne, G. W., et al.
Publicado: (1998) -
Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
por: Freemantle, S. J., et al.
Publicado: (1995) -
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
por: Smith, I., et al.
Publicado: (1996) -
Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
por: Judson, I., et al.
Publicado: (1998) -
The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.
por: Walton, M. I., et al.
Publicado: (1998)